Bing YaoChairman and CEO at Viela Bio
Bing Yao is the CEO of Viela Bio. Inc, a new spin-out from AstraZeneca/MedImmune. Viela Bio is developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of disease. Bing has spent more than two decades in the biopharmaceutical industry, has a track record of leading successful discovery and development of multiple biotherapeutics. Prior to Viela Bio, he was Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED, MedImmune. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology diseases respectively. Bing was also Senior Vice President, Head of ImmunoOncology Franchise, AstraZeneca. Before MedImmune, Bing held multiple positions with increasing responsibilities at Genentech, Aventis, Tanox, and Amgen. Bing is also on the Board of Directors for NexImmune. Bing received his Ph.D. in Microbiology and Immunology from the University of Iowa.